DIFENE Modified‑release capsule Ref.[49772] Active ingredients: Diclofenac

Source: Υπουργείο Υγείας (CY)  Revision Year: 2016  Publisher: Medililink Pharmaceuticals Ltd, 30 Armenias Street, 2003 Strovolos, Nicosia, Cyprus, Tel.: +357 22319282, Fax: +357 22319290

4.1. Therapeutic indications

Symptomatic treatment of pain and inflammation in:

  • Acute arthritis (including attacks of gout)
  • Chronic arthritis, including rheumatoid arthritis (chronic polyarthritis)
  • Ankylosing spondylitis (Bechterew’s Disease) and other inflammatory rheumatic diseases of the spinal column
  • Painful conditions associated with arthritis and spondylarthropathy
  • Inflammatory rheumatic diseases of soft tissue
  • Painful swelling or inflammation after injury.

Because the release of active substance from Difene Dual Release 100mg is delayed, this preparation is not suitable for starting treatment in conditions where rapid onset of action is needed.

4.2. Posology and method of administration

Dosage

The dose of diclofenac depends on the severity of the condition. The recommended dose range for adults lies between 50 and 100 mg diclofenac sodium per day.

Age Single dose: Number of Difene Dual Release 100mg modified‑release capsules, hard Total daily dose: Number of Difene Dual Release 100mg modified‑release capsules, hard
Adults1 (equivalent to 100 mg diclofenac sodium) 1 (equivalent to 100 mg diclofenac sodium)

Method and duration of administration

Difene Dual Release 100mg is taken without chewing and with plenty of fluid. Those with sensitive stomachs are recommended to take Difene Dual Release 100mg during meals.

The patient’s doctor decides the length of administration. For rheumatic diseases, it can be necessary to take Difene Dual Release 100mg for a long time.

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4 Special warnings and precautions for use).

Special groups of patients

Elderly patients

No specific dose adjustment is required. Because of the potential undesirable effect profile, elderly patients should be monitored with particular care.

Impaired renal function

For patients with mildly to moderately impaired renal function no dose reduction is required (for patients with severe renal impairment see section 4.3).

Hepatic dysfunction (see section 5.2)

For patients with mild to moderate hepatic dysfunction no dose reduction is required (for patients with severe hepatic dysfunction see section 4.3).

Children and adolescents

For use in children and adolescents see also section 4.3.

4.9. Overdose

Symptoms of overdose

Symptoms of overdose can be central nervous system disorders, such as headache, dizziness, drowsiness and loss of consciousness (in children, also myoclonic seizures), and abdominal pain, nausea and vomiting. Gastrointestinal bleeding and liver and kidney dysfunction are also possible. Hypotension, respiratory depression and cyanosis may occur.

Treatment of overdose

No specific antidote exists.

6.3. Shelf life

he shelf life is 4 years.

This medicinal product should not be used after the expiry date.

6.4. Special precautions for storage

Do not store above 25°C.

Store in the original package in order to protect from moisture.

6.5. Nature and contents of container

Blister packs of PVC/PVDC foil and aluminium foil.

Original pack of 10, 20, 50, 100 modified‑release capsules, hard.

Hospital pack of 500 (10 × 50) modified‑release capsules, hard.

6.6. Special precautions for disposal and other handling

No special requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.